Document:

WWW.EXFILE.COM, INC. -- 13648 -- BOSTON SCIENTIFIC CORP. -- EXHIBIT 10.1 TO FORM 8-K

EXHIBIT 10.1 

    

      FORM OF
SETTLEMENT
        AGREEMENT

       

      I. 
        PARTIES

       

      

      This
        Settlement Agreement (“Agreement”) is entered into between the United States of
        America, acting through the United States Department of Justice and on behalf
        of
        the Food and Drug Administration (“FDA”) of the Department of Health and Human
        Services (“HHS”) (collectively the “United States”); and Boston Scientific
        Corporation (“Boston Scientific”) (hereafter referred to as “the Parties”),
        through their authorized representatives.

       

      II. 
        RECITALS

       

       

      WHEREAS,
        Boston Scientific is a publicly traded Delaware corporation with a principal
        place of business in Natick, Massachusetts. At all times relevant to this
        Agreement, Boston Scientific manufactured and marketed medical devices
        throughout the United States and internationally, and had an indirect,
        wholly-owned subsidiary, Scimed Life Systems, Inc. (“Scimed”). Scimed was
        located in Maple Grove, Minnesota, and was in the business of manufacturing
        and
        distributing various medical devices, including heart catheters and premounted
        coronary stent delivery systems;

      

      WHEREAS,
        at all times relevant to this Agreement, Boston Scientific and its Scimed
        subsidiary were engaged in manufacturing, packing, storing and introducing
        into
        interstate commerce a medical device called the NIRTM
        ONTM
        RangerTM
        with SOX
        (“NORS”) premounted coronary stent delivery system. Boston Scientific through
        its Scimed subsidiary regularly manufactured the NORS from certain components
        received in interstate commerce and introduced, following FDA approval, the
        NORS
        into interstate commerce for shipment throughout the United States;

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      

       

      WHEREAS,
        the United States alleges that from August 12, 1998, through and including
        October 5, 1998, Boston Scientific and its Scimed subsidiary shipped 34,589
        NORS
        premounted coronary stent delivery system devices to hospital catheterization
        laboratories in violation of the Federal
        Food, Drug, and Cosmetic Act (“the FDCA”), 21 U.S.C. § 331(a). These allegations
        are explained in detail in a Complaint filed by the United States in the
        United
        States District Court, District of Massachusetts, on June 24, 2005, and are
        referred to herein as “Covered Conduct;”

       

      WHEREAS,
        the United States contends that through its distribution of adulterated and
        misbranded medical devices, Boston Scientific obtained gains including proceeds
        and profits to which it was not lawfully entitled, and that the United States
        is
        entitled to equitable disgorgement;

      

      WHEREAS,
        the United States further contends that it may have certain civil and
        administrative claims or causes of action against Boston Scientific concerning
        the Covered Conduct;

      

      WHEREAS,
        Boston Scientific does not admit to the allegations in the Complaint and
        specifically denies each and every allegation of wrongdoing;

       

      WHEREAS,
        the United States is not making any concessions that its claims are not well
        founded;

      

      WHEREAS,
        the Parties mutually wish to avoid the delay, expense, inconvenience, and
        uncertainty of protracted litigation, and to reach settlement under the FDCA
        as
        to the Covered Conduct;

       

      -2-

      Settlement
        Agreement

      U.S.and
        Boston Scientific

      June
        24, 2005

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      WHEREAS,
        this Agreement is made in compromise of disputed claims. Neither the Agreement,
        its execution, or the performance of any obligations under it, including
        any
        payments, nor the fact of the settlement, is intended to be, or shall be
        understood as, an acknowledgment of responsibility, admission of liability
        or
        wrongdoing, or other expression reflecting upon the merits of the dispute
        by
        Boston Scientific, Scimed or any of their agents or employees.
 

      III. 
        TERMS AND CONDITIONS

       

      NOW,
        THEREFORE, in reliance upon the representations contained herein and in
consideration
        of the mutually negotiated promises, covenants, and obligations in this
        Agreement, and for good and valuable consideration, receipt of which is by
        each
        acknowledged, the Parties agree as follows:

       

      1. Within
        five (5) business days from the effective date of this Agreement, Boston
        Scientific shall pay the United States the sum of Seventy-Four-Million dollars
        ($74,000,000.00) (the “Settlement Amount”). Boston Scientific agrees to pay the
        Settlement Amount by electronic funds transfer pursuant to written instructions
        to be provided by the United States Attorney's Office for the District of
        Massachusetts.

      

      2. Upon
        verified receipt by the United States of the full Settlement Amount, the
        United
        States shall file its Complaint and the United States and Boston Scientific
        shall file a joint stipulation providing for the dismissal with prejudice
        of the
        Complaint. The stipulation shall provide that the Parties shall each bear
        its
        own costs and attorneys' fees incurred in connection with the action and
        that
        all rights of appeal are waived.

       

      -3-

      Settlement
        Agreement

      U.S.and
        Boston Scientific

      June
        24, 2005

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      3. Subject
        to the exceptions below and conditioned upon the payment in full of the
        Settlement Amount, the United States (on behalf of itself, its officers,
        agents,
        agencies, and departments) releases Boston Scientific and its parents,
        affiliates, divisions, subsidiaries, predecessors, successors, assigns,
        transferees, and their respective current and former directors, officers,
        shareholders, agents, attorneys, and employees from any civil common law
        or
        equitable claim, sanction or remedy that the United States has or may have
        based
        on the Covered Conduct, actionable under the FDCA.

       

      4. Boston
        Scientific and its parents, affiliates, divisions, subsidiaries, predecessors,
        successors, assigns, transferees, and their respective current and former
        directors, officers, shareholders, agents, attorneys, and employees release
        any
        civil common law or equitable claims, of whatever kind, against the United
        States, its officers, agents, attorneys, and employees, arising out of or
        relating to the Covered Conduct or the government's investigation of the
        Covered
        Conduct, actionable under the FDCA.

       

      5. The
        Parties agree that the statute of limitations tolling agreement, originally
        signed on September 17, 2004 and extended through June 24, 2005 (“SOL Tolling
        Agreements”), shall remain in effect until the filing of the joint stipulation
        of dismissal by the Parties. Upon the filing of the joint stipulation of
        dismissal by the Parties, the Parties agree that the SOL Tolling Agreements
        are
        abrogated and are null and void and are of no effect.

       

      -4-

      Settlement
        Agreement

      U.S.and
        Boston Scientific

      June
        24.
        2005

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      6. Notwithstanding
        any term of this Agreement, specifically reserved and excluded from the scope
        and terms of this Agreement as to any entity or person are any and
        all:

      

      (a)
        claims that the United States may have for personal injury or property damage
        or
        for other consequential damages arising from products or services delivered
        or
        caused to be delivered to the United States;

      

      (b)
        any
        claims the United States may have under the False Claims Act, 31 U.S.C. §§
        3729, et seq.;

      

      (c)
        claims based on such obligations as are created by this Agreement;

      

      (d)
        claims that the United States may have under the Internal Revenue Code; Title
        26
        of the United States Code;

       

      (e)
        liability to the United States (or any agencies thereof) for any conduct
        other
        than that released herein;

      

      (f)
        any
        liability to the United States for failure to deliver goods or services due;
        and

      

      (g)
        any
        criminal liability.

      

      7. All
        costs
        (as defined by the Federal Acquisition Regulations (“FAR”), 48 C.F.R. §
        1-31.205-47) incurred by or on behalf of Boston Scientific and its parents,
        affiliates, divisions, subsidiaries, predecessors, successors, assigns,
        transferees, and their respective current and former directors, officers,
        shareholders, agents, attorneys, and employees in connection with (1) the
        matters covered by this Agreement; (2) the United States' audit(s) and
        investigation(s) of the matters covered by this Agreement; (3) Boston
        Scientific’s investigation, defense, and corrective actions with respect to the
        matters covered by this Agreement (including costs and attorneys' fees);
        (4) the
        negotiation of this Agreement; and (5) the payment Boston Scientific makes
        to
        the United States pursuant to this Agreement, shall be "unallowable costs"
        for
        government contract accounting purposes. These unallowable costs will be
        separately determined and accounted for

       

      -5-

      Settlement
        Agreement

      U.S.and
        Boston Scientific

      June
        24.
        2005

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      by
        Boston
        Scientific and Boston Scientific will not charge such unallowable costs directly
        or indirectly to any contracts with the United States or seek payment of
        such
        unallowable costs.

       

      8. This
        writing constitutes the entire agreement of the Parties with respect to the
        subject matter of this Agreement. There are no other agreements, understandings,
        representations, warranties, inducements, or considerations regarding the
        subject matter of this Agreement, except as expressly stated
        herein.

       

      9. This
        Agreement may not be modified, amended or terminated except by a written
        agreement signed by the Parties specifically referring to this
        Agreement.

       

      10. The
        Parties’ rights not expressly released in this Agreement are
        reserved.

       

      11. This
        Agreement is intended to be for the benefit of the United States and Boston
        Scientific, and by this instrument the Parties do not waive, compromise,
        or
        release any claims or causes of action against any other person or entity
        not
        expressly released by this Agreement.

       

      12. Nothing
        in this Agreement constitutes an agreement by the United States concerning
        the
        characterization of the amounts paid hereunder for purposes of any proceeding
        under Title 26 of the U.S. Code (Internal Revenue Code).

       

      13. Except
        for the release provided to the United States in Paragraph 4 of this Agreement,
        nothing in this Agreement shall preclude or otherwise affect the right of
        Boston
        Scientific to pursue and obtain contribution or indemnification from any
        other
        person or entity arising out of or related to the Covered Conduct.

       

      -6-

      Settlement
        Agreement 

      U.S.and
        Boston Scientific 

      June
        24, 2005

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      14. The
        Parties consent to the United States’ and Boston Scientific’s disclosure of this
        Agreement, and information about this Agreement, to the public.

       

      15.
        This
        Agreement is governed by the laws of the United States. The Parties agree
        that
        the exclusive jurisdiction for any disputes arising between and among the
        Parties under this Agreement will be the United States District Court for
        the
        District of Massachusetts.

       

      16. The
        Parties represent that this Agreement is freely and voluntarily entered into
        without any degree whatsoever of duress or compulsion. No provision of this
        Agreement shall be construed against any party by reason of such party having
        drafted such provision of this Agreement.

       

      17. Each
        person who signs this Agreement warrants that he or she is duly authorized
        to do
        so, as does the party on behalf of whom such person signs.

       

      -7-

      Settlement
        Agreement 

      U.S.and
        Boston Scientific 

      June
        24, 2005

       

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      18. This
        Agreement is effective on the date of the last signature to it. Facsimiles
        of
        signatures shall constitute acceptable, binding signatures for purposes of
        this
        Agreement.

       

      19.
        The
        Parties have executed four (4) identical copies of this Agreement, each of
        which
        shall be deemed an original of this Agreement.

       

      
        	
                For
                  BOSTON SCIENTIFIC

              	
                For
                  the UNITED STATES

              
	 	 
	 	
                MICHAEL
                  J. SULLIVAN

              
	 	
                United
                  States Attorney

              
	 	
                District
                  of Massachusetts

              
	 	 
	 	
                PETER
                  D. KEISLER

              
	 	
                Assistant
                  Attorney General

              
	 	
                Civil
                  Division

              
	 	
                United
                  States Department of Justice

              
	 	 
	 	 
	
                 
                  
                  

                

                PAUL
                  SANDMAN, Esquire

              	
                 
                  
                  

                

                MICHAEL
                  K. LOUCKS

              
	
                General
                  Counsel and

              	
                First
                  Assistant United States Attorney

              
	
                Authorized
                  Representative of

              	
                District
                  of Massachusetts

              
	
                Boston
                  Scientific Corporation

              	
                JAMES
                  E. ARNOLD

              
	 	
                Assistant
                  United States Attorney

              
	 	
                Deputy
                  Chief, Health Care Fraud

              
	 	
                District
                  of Massachusetts

              
	 	
                JAMES
                  J. MCGOVERN

              
	
                 
                  
                  

                

                ROBERT
                  D. KEEFE, Esquire

              	
                Assistant
                  United States Attorney

                
                  ANTON
                    P. GIEDT

                  
                    Assistant
                      United States Attorney

                  

                

              
	
                
                  Wilmer
                    Cutler Pickering Hale and Dorr

                

              	
                 

              
	
                
                  60
                    State Street

                

              	
                 

              
	
                
                  Boston,
                    Massachusetts 02109

                

              	
                 
                   
                  

                

                EUGENE
                  M. THIROLF 

              
	
                 

              	
                Director 

              
	 	
                
                  Office
                    of Consumer Litigation

                

              
	 	
                
                  United
                    States Department of Justice

                

              
	 	
                 

              
	 	
                 

              
	 	
                 

              
	Date:
                June 24, 2005 	 

      

      

      

      -8-

       

      Settlement
        Agreement 

      U.S.and
        Boston Scientific 

      June
        24, 2005Exhibit 4.7

 

THIS SETTLEMENT AGREEMENT is made on 24 February 2005

 

B E T W E E N:

 

(1)           THALES SA, a French
société anonyme having its registered office at 45 rue de Villiers, Neuilly sur
Seine (92200) (“Thales”); and

 

(2)           NICE  SYSTEMS LTD. an Israeli company having its registered office
at 8 Hapnina Street, Ra’anana, 43107 Israel (“Nice”); and

 

(3)           NICE CTI SYSTEMS UK
LIMITED (a company incorporated in England and Wales with registered number
03403044) whose registered office is at Tollbar House, Tollbar Way, Hedge End,
Southampton, Hampshire SO30 2ZP; and

 

(4)           NICE
SYSTEMS SARL, a French société
a responsabilité limitée  having its
registered office at 110/112 boulevard Jeans Jaures, 92100, Boulogne
Billancourt,  France; and

 

(5)           NICE
SYSTEMS GMBH (a German company) whose registered office is at Lyonerstrasse
44-48, Frankfurt 60528, Germany; and

 

(6)           NICE
SYSTEMS INC. (a company incorporated under the laws of the State of
Delaware , USA), whose principal place of business is at 301 Route 17
North, Rutherford, New Jersey 07070; (together “the Subsidiaries”).

 

WHEREAS:

 

A            Thales,
Nice and the Subsidiaries signed a Sale and Purchase Agreement on 30 July 2002
in connection with the acquisition by Nice of certain assets and liabilities of
Thales Contact Solutions Limited, Thales Contact Solutions S.A. Thales Contact
Solutions GmbH and Thales Contact Solutions Inc. (the “SPA”).

 

B             The
SPA contained various price adjustment mechanisms and indemnities related to
the assets sold to Nice.

 

1

 

C             On
8 September 2004, Nice notified claims to Thales pursuant to Clause 15 (“Debts
and Accounts Receivable”), Clause 16 (“Inventory”), and Clause 18 (“Instem
Manufacturing Agreement”) of the SPA (the “Claims”).

 

D             Nice,
Thales and the Subsidiaries have agreed the following terms of settlement in
respect of the price adjustment mechanisms under the SPA and, in particular, in
respect of any and all claims which Nice and the Subsidiaries may have against
Thales howsoever and whensoever arising out of Clauses 15, 16 and 18.

 

IT IS AGREED as
follows:

 

1.                      In this
Settlement Agreement, save where the context otherwise requires:

 

1.1.                   words and
expressions defined in the SPA shall have the same meanings in this Settlement
Agreement;

 

1.2.                   words in
the singular shall include the plural, and vice versa;

 

1.3.                   except if
provided differently in this Settlement Agreement a reference to a clause or
sub-clause shall be a reference to a clause or sub-clause (as the case may be)
of the Settlement Agreement;

 

1.4.                   the
headings in this Settlement Agreement are for convenience only and shall not
affect the interpretation of any provision of this Settlement Agreement;

 

1.5.                   references
to a “Party” or the “Parties” are to a party or the parties to this Settlement
Agreement;

 

1.6.                   references
to the SPA shall include any amendment thereto entered into between the
Parties.

 

2.                      SETTLEMENT

 

2.1.                   In
consideration of:

 

2.1.1.                the
payment by Thales to Nice of the sum of USD 2,130,000 (two million one hundred
thirty thousand United States dollars); and

 

2

 

2.1.2.                the
payment by Thales ATM, or failing that by Thales, to Nice of €89,399.40 (eighty
nine thousand three hundred ninety nine point forty euros) in respect of an invoice
numbered “90201” due by Thales ATM to Nice;

 

2.1.3.                Thales’
agreement that Nice and the Subsidiaries may retain the benefit of the Accounts
Receivable and the Inventory and need not account to it by way of reassignment
of Accounts Receivable or the return of Unsold Inventory as otherwise required
by Clauses 15 and 16 of the SPA respectively or at all,

 

Nice and the Subsidiaries agree that:

 

2.1.4.                such
payments are in full and final settlement of the Claims and (except as provided
at clause 2.2) hereby release Thales and its subsidiaries from all and any
actual or potential claims or complaints of whatsoever nature, howsoever and
whensoever arising, whether known or unknown, that any of them and/or any
parent, subsidiary, associated or group company of any of them (and/or their
respective employees and/or officers and/or former employees and/or former
officers) has or may have against Thales or any of its subsidiaries which have
arisen or may arise out of, or which are connected with the price adjustment
mechanisms under the SPA and, in particular, in respect of any and all claims
which Nice may have against Thales and/or any of its subsidiaries howsoever and
whensoever arising out of Clauses 15, 16 and 18 of the SPA; and

 

2.1.5.                such
payments are in full and final settlement of all Accounts Receivable and other
amounts owed by Thales and its subsidiaries in respect of goods and/or services
supplied to any of them by the TCS Group as at or prior to the Completion Date
and hereby release Thales and its subsidiaries from all and any actual or
potential claims or complaints of whatsoever nature, howsoever and whensoever
arising, whether known or unknown, that any of them may have against Thales
and/or any of its subsidiaries howsoever and whensoever

 

3

 

arising in respect of such supplies,
save in respect of the payment required under clause 2.1.2 above.

 

2.2.                   Nothing
in this Settlement Agreement shall operate to settle, waive, compromise or in
anyway prejudice any right of Nice and/or the Subsidiaries with respect to any
existing and/or potential claim or claims arising pursuant to the SPA which are
not connected with the price adjustment mechanisms and/or Clauses 15, 16 and 18
of the SPA, including, without limitation, claims pursuant to Clauses 3
(Business Properties), 6 (Liabilities to be Assumed), 11 (Indemnities), 14
(Employment), 17 (Warranty Work and Additional Services), 20 (Insurance
Claims), 22 (Warranties and Limitation of Liability) and 25 (Pensions), howsoever
and whensoever arising.

 

2.3.                   This
Settlement Agreement may be signed in counterpart copies and Nice agrees to fax
a copy of this Settlement Agreement, executed respectively by an officer with
the necessary authority to Thales (fax
number: +33 1 57 77 84 77 for the attention of: Olivier MAS) by 10am
London time on         February 2005.
Thales agrees to fax a copy of this Agreement, executed by an officer with the
necessary authority, to Nice (fax number:+44
8707 22 4042, for the attention of: John MALINS) by 10am London time
on         February 2005.

 

2.4.                   After
Thales and Nice have confirmed receipt of the faxes mentioned above by
telephone (Thales to telephone John MALINS
at Nice on +44 8707 22 4042),

 

2.4.1.                Thales
shall pay to Nice the sum at clause 2.1.1 above within five business days of
the signature of this Settlement Agreement, and

 

2.4.2.                Thales
ATM, or failing that Thales, shall pay to Nice the sum at clause 2.1.2 above,
within sixty calendar days of the signature of this Settlement Agreement.

 

4

 

2.5.                   Nice
agrees to forward the original of the Agreement faxed to Thales, to Thales (for the attention of: Olivier MAS, Thales SA, 45 rue
de Villiers – 92200 Neuilly sur Seine). Thales agrees to forward the
original signed Agreement faxed to Nice, to Nice (for the attention of: Stephen DUNNE, NICE CTI Systems UK Limited,
Tollbar House, Tollbar Way, Hedge End, Southampton, Hampshire SO30 2ZP).

 

2.6.                   Thales
shall make the payment at clause 2.1.1 to:

 

Nice
Systems Limited

 

CITIBANK
(TEL AVIV)

 

SWIFT
CODE: _CITIILIT

 

Account Number: 500079029 (through ac. No. 36154271 of
Citibank Tel Aviv with Citibank New York (citius33).

 

2.7.                   Thales
ATM or alternatively Thales shall make the payment at clause 2.1.2 to:

 

Nice
Systems SARL

 

CITIBANK

 

SWIFT
CODE: CTIFRPP IBAN:FR76 1168 9007 0000 6550 6300 522

 

Account
Number: 655063005-22.

 

2.8.                   If
payment of any sum due to be paid under this Settlement Agreement is not made
by Thales or, as the case may be, Thales ATM, on or before the due date for
payment then interest shall accrue on the amount outstanding for the period
from the due date to the date of actual payment at the rate of 3% above the
base rate of Barclays Bank plc computed on a daily basis until and including
the date of payment.

 

3.                      CONFIDENTIALITY

 

3.1.                   The terms
of this Settlement Agreement and all facts and matters relating to its
subject-matter (including the nature and details of the claims and events
leading up to them, all pleadings, documents, evidence submitted and the
negotiations which have led up to this Settlement Agreement) are confidential
and the Parties whether by their directors or officers, servants, agents or
otherwise, agree to keep the terms of this

 

5

 

Settlement Agreement and all facts and
matters relating to its subject-matter (including the nature and details of the
claims and events leading up to them, all documents, evidence submitted and the
negotiations which have led up to this Settlement Agreement) confidential and
agree not to disclose the contents of the Settlement Agreement (or related
facts and matters) to any third party other than their professional legal
advisers and accountants, save to the extent that such disclosure is required
by law or regulation to which a Party is subject or for the purposes of
enforcing this Settlement Agreement or is permitted by a prior written
agreement of the Parties to this Settlement Agreement such agreement not to be
unreasonably withheld.

 

3.2.                   For the avoidance of doubt, nothing in this Settlement
Agreement shall prevent any Party or any parent, subsidiary, associated or
group company of any Party disclosing these terms of settlement in connection
with any disposal of a Party and/or any parent, subsidiary, associated or group
company of any Party providing that any third party to whom disclosure is made
has previously agreed in writing to treat such disclosure as confidential as
set out at paragraph 3.1 above.

 

4.     MISCELLANEOUS

 

4.1           This
Settlement Agreement shall be binding on and enure for the benefit of the
successors and permitted assigns of the Parties.

 

4.2           The
benefit of this Settlement Agreement may not be assigned by any Party without
the prior written consent of the others.

 

4.3           This Settlement
Agreement constitutes the entire agreement between the Parties in relation to
the subject matter of this Settlement Agreement.  Each Party acknowledges and confirms that in
entering into this Settlement Agreement it is not relying upon any statement or
representation made by or on behalf of any of the other Parties, whether or not
in writing, at any time prior to the execution of this Settlement Agreement,
which is not expressly set out herein. Each of the Parties expressly agrees
that it will not have any right of action in relation to any statement 

 

6

 

or representation, whether oral or
written, made by or on behalf of any other Party in the course of any
negotiations which preceded the execution hereof, unless such statements or
representations were made fraudulently. This Settlement Agreement may be varied
or modified only by the written agreement of the Parties.

 

5.     SEVERABILITY

 

If any provision of this Settlement
Agreement shall be held to be illegal or unenforceable, whether in whole or in
part in relation to any of the Parties to the Settlement Agreement, the
validity and enforceability of the remainder of the Settlement Agreement, or
its validity or enforceability as against other parties, shall not be affected.

 

6.     COSTS

 

Each Party will bear its own legal
costs arising to date, including any costs arising out of the negotiation and
execution of this Settlement Agreement.

 

7.     NOTICES

 

7.1           A notice,
approval, consent or other communication in connection with this Settlement
Agreement must:

 

7.1.1        be in writing;

 

7.1.2        in the case of
Thales be marked for the attention of Mr Olivier MAS and left at the following
address:

 

THALES S.A. 45 rue de Villiers 92200
Neuilly sur Seine ;

 

7.1.3        in the case of Nice
and/or the Subsidiaries be marked for the attention of Mr Stephen DUNNE, and
left at the following address:

 

NICE CTI Systems UK Limited, Tollbar
House, Tollbar Way, Hedge End, Southampton, Hampshire SO30 2ZP.

 

7.2.         A notice,
approval, consent or other communication shall take effect from the time it is
received (or, if earlier, the time it is deemed to be received in accordance
with sub-clause 7.3) unless a later time is specified in it.

 

7

 

7.3.         A letter
is deemed to be received, unless actually received earlier, on the seventh day
after posting.

 

8.     GOVERNING
LAW, JURISDICTION AND SERVICE OF PROCESS

 

8.1           This
Settlement Agreement shall be governed by and construed in accordance with
English law.

 

8.2.         In
relation to any disputes arising out of or in connection with this Settlement
Agreement, the Parties shall first use all reasonable endeavours to resolve
amicably such matters between them. 
Failing such resolution, such disputes shall be finally settled in the
courts of England.

 

8.3.         Each
Party agrees that, without preventing any other mode of service, any document
in an action may be served on any Party by being delivered to or left for that
Party at the address as provided in the paragraph headed “Notices” above.

 

8

 

IN WITNESS of which the Parties have executed this Settlement
Agreement on the date first mentioned above

 

 

SIGNED on behalf of

THALES-SA

 

In the presence of:

 

SIGNED on behalf of

NICE SYSTEMS LTD

 

In the presence of:

 

SIGNED on behalf of

NICE CTI SYSTEMS UK LIMITED

 

In the presence of:

 

SIGNED on behalf of

NICE SYSTEMS SARL,

 

In the presence of:

 

SIGNED on behalf of

NICE SYSTEMS GMBH

 

In the presence of:

 

SIGNED on behalf of

NICE SYSTEMS INC.

 

In the presence of:

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]